About this trial
Our primary objective is to increase HIV pre-exposure prophylaxis (PrEP) awareness and uptake among people who want, need, or would benefit from PrEP in Dallas, TX through a pilot program of immediate PrEP prescribing in the Parkland Memorial Hospital Emergency Department (ED) with linkage to PrEP clinic. Leveraging the previous work of the Parkland Center for Clinical Innovation (PCCI) which created an automated electronic health record (EHR) based HIV prediction tool and prior success with a robust ED HIV navigation program, a PrEP navigator would approach patients in the Parkland ED for PrEP initiation. Through standard care prescribing by their ED clinician, subjects would leave the ED with a prescription for rapid-start oral PrEP and a clinic appointment to persist on the PrEP modality of their choice which will include long-acting injectable options.
Eligibility criteria
Qualifiers
Able to comprehend and provide signed, written informed consent prior to initiation of study procedures.
Negative HIV rapid test
Requesting PrEP from their ED clinician
Score >75% on the PCCI HIV Prediction Tool
Disqualifiers
Known diagnosis of HIV
Positive HIV rapid test
Current use of PrEP, which is defined for purposes of this study as use of PrEP in the last 4 weeks
Known hypersensitivity or allergy to any PrEP modality
Trial design
Treatments tested in this trial
- PrEP Uptake with Rapid Start
- Pre-Exposure Prophylaxis (PrEP) Persistence
Treatment groups
Sponsors and collaborators
University of Texas Southwestern Medical Center
Lead sponsor
Gilead Sciences
Collaborator